Blood Cancer Breakthroughs: How Expanded Cord Blood is Saving Lives

Expanded cord blood therapy is transforming blood cancer treatment by solving a long-standing issue: low stem cell counts in standard cord blood transplants. With FDA-approved therapies like Omidubicel (Omisirge), stem cell counts have increased from fewer than 200,000 cells per kilogram to 6 million cells per kilogram, leading to faster recovery and fewer infections. Key benefits include:

• Faster recovery: Neutrophil recovery in 12 days vs. 22 days with standard cord blood.
• Lower infection rates: 39% vs. 60% within the first 100 days.
• Broader donor pool: No perfect HLA match required, helping 95% of racial-minority patients.

These advancements are giving new hope to patients with leukemia, lymphoma, and other blood cancers. Private cord blood banking ensures access to these therapies, making it a critical step for families planning for future medical needs.

What Is Expanded Cord Blood Therapy?

Defining Expanded Cord Blood

Expanded cord blood therapy involves isolating and multiplying stem cells from a single unit of umbilical cord blood for transplantation. This process, known as ex vivo expansion, addresses the challenge of low cell counts in standard cord blood units - typically less than 200,000 cells per kilogram - making them inadequate for adult patients.

Through expansion, the number of CD34+ cells increases significantly, averaging a 164-fold boost. As a result, expanded units can deliver around 6 million CD34+ cells per kilogram, providing a cell dose that rivals or even surpasses bone marrow vs. cord blood transplants.

The process uses various techniques to enhance the cell dose while maintaining their effectiveness:

• Nicotinamide (Vitamin B3): Helps preserve the cells' ability to differentiate.
• Notch signaling: Ensures the cells retain their potency.
• UM171: Rejuvenates stressed cells.

These methods collectively elevate the therapeutic potential of the expanded cells, enabling a dose sufficient for faster immune recovery and improved transplant outcomes.

How Expanded Cord Blood Fights Blood Cancers

The higher cell dose plays a critical role in speeding up recovery, a vital factor in treating blood cancers. Expanded cord blood accelerates the regeneration of bone marrow and blood cells, quickly restoring essential components like white blood cells (neutrophils) and platelets. These are crucial for fighting infections and preventing bleeding.

Clinical results highlight the impact of this accelerated recovery. Among patients receiving expanded cord blood, 94% achieved successful engraftment within six weeks. Key recovery milestones include:

• Neutrophil recovery: A median of 11.5 days with expanded cells, compared to 21 days with standard cord blood.
• Platelet recovery: Reduced from 46 days to 34 days.

Dr. Mitchell Horwitz from Duke Cancer Institute emphasized the importance of this speed:

"It's when their blood counts are low that patients are most vulnerable to infections, so by reducing that time to 11.5 days, we shorten that vulnerable period."

This faster recovery directly improves outcomes. Patients treated with expanded cord blood experienced bacterial or fungal infections 39% of the time within the first 100 days post-transplant, compared to 60% with standard cord blood. By minimizing the risk of life-threatening infections and complications, expanded cord blood therapy offers a crucial advantage in improving survival rates and overall patient health.

Major Advances in Expanded Cord Blood Therapies

These developments are reshaping stem cell transplantation, offering new possibilities for patients who previously had limited treatment options.

Omidubicel: Faster Recovery Times

Omidubicel, marketed as Omisirge, became the first FDA-approved expanded cord blood product in April 2023. It uses nicotinamide technology, a form of Vitamin B3, to expand cord blood stem cells while maintaining their functionality. This process produces a dual-fraction graft: expanded CD133⁺ cells for quicker recovery and non-expanded CD133⁻ cells with T-cells to reduce graft failure risks. Together, these components help stem cells home to the bone marrow more efficiently, speeding up engraftment.

Between 2013 and 2020, a multicenter Phase 3 trial led by Dr. Mitchell Horwitz evaluated Omidubicel in 125 patients aged 12–65 with high-risk blood cancers. Published in Blood, the study revealed impressive results: the median time to neutrophil recovery dropped to 12 days with Omidubicel, compared to 22 days with standard cord blood transplants. Platelet recovery also improved, with a reduction from 50 days to 37 days, and 87% of patients achieved neutrophil recovery. Additionally, infection rates were lower - 37% to 39% of Omidubicel patients experienced bacterial or fungal infections within 100 days, compared to 57% to 60% with standard transplants.

Dr. Peter Marks, Director of the FDA's Center for Biologics Evaluation and Research, emphasized the therapy's significance:

"Hastening the return of the body's white blood cells can reduce the possibility of serious or overwhelming infection associated with stem cell transplantation."

In December 2025, the FDA expanded Omidubicel's approval to include patients aged 6 and older with severe aplastic anemia. While it accelerates recovery, other therapies like NK cell therapy focus on targeting specific cancers.

NK Cell Therapy: Targeting Lymphoma

Natural killer (NK) cell therapy, derived from cord blood, offers a specialized approach for lymphoma treatment. These immune cells can destroy cancer cells without needing a perfect donor-recipient match. They also pose a lower risk of graft-versus-host disease while maintaining strong anti-cancer effects. This makes NK cell therapy a promising option for patients with lymphoma, complementing broader advancements in cord blood treatments.

For high-risk adult patients, Zemcelpro UM171 provides another critical option.

Zemcelpro UM171: Expanding Access for High-Risk Patients

In August 2025, Zemcelpro earned conditional approval from the European Commission, marking it as the first expanded cord blood therapy approved in Europe. It uses UM171 (dorocubicel), a proprietary molecule, to expand stem cells from a single cord blood unit, making transplants possible for adults who previously lacked sufficient cells.

This therapy is designed for adults with high-risk blood cancers, such as leukemias and myelodysplastic syndromes, who lack a suitable donor match. Clinical trials reported 70% cancer-free survival at two years, a significant improvement over the typical 40% rate. Patients achieved neutrophil engraftment in a median of 18 days.

François Lucas Alzate, a 23-year-old from Montreal diagnosed with acute myeloid leukemia in 2016, underwent UM171-expanded cord blood treatment at Maisonneuve-Rosemont Hospital. As of August 2025, he remains disease-free.

Professor Emilian Snarski, Medical Director at FamiCord Group, highlighted the therapy's transformative potential:

"Retrospective data suggest expanded cord blood not only lowers relapse rates but also reduces the risk of graft-versus-host disease compared to many other donor sources. If these outcomes are confirmed in prospective trials, this could be the most significant advance in transplantation since CAR-T therapy."

Expanded Cord Blood vs. Standard Transplants

Benefits of Expanded Cord Blood

Expanded cord blood transplants work by multiplying stem cells, which enhances their effectiveness, particularly for adult patients. One of the most notable benefits is the faster recovery of neutrophils - patients receiving expanded cord blood experience this recovery about 10 days sooner. This speed is crucial, as it lowers the risk of severe infections during the vulnerable period when the immune system is rebuilding. On top of that, patients are typically discharged 13 days earlier (48 days compared to 61 days) after their transplant.

Dr. Zachariah DeFilipp, an expert in hematopoietic stem cell transplantation, highlighted the impact of this approach:

"Omidubicel significantly improves the engraftment after transplant, as compared to standard cord blood transplant. For patients lacking an HLA-matched donor, this approach can help overcome the extended periods of low blood cell counts seen in standard transplants."

This method also expands the donor pool, which is especially important for underserved minority groups who often struggle to find HLA-matched donors. Below is a side-by-side comparison of key metrics.

Comparison Table: Expanded vs. Standard Cord Blood Transplants

Metric	Standard Cord Blood	Expanded Cord Blood (Omidubicel)
Median Neutrophil Recovery	22 days	12 days
Platelet Recovery by Day 42	35%	55%
Grade 2-3 Bacterial/Fungal Infections	57–60%	37–39%
Grade 3 Viral Infections (1 year)	26%	10%
Median Days Out of Hospital (Day 100)	48 days	61 days
Neutrophil Engraftment Success	89%	96%
Patient Eligibility	Limited by cell dose	Broadened; uses smaller units

Patient Success Stories with Expanded Cord Blood

Patient experiences bring expanded cord blood's impact to life, showing how advancements in medicine translate into real-world victories. In December 2025, a National Institutes of Health (NIH) clinical trial, led by Dr. Richard Childs, shared outcomes for 18 patients aged 4 to 60 who were battling severe aplastic anemia. The trial utilized omidubicel and achieved a 94% survival rate, with neutrophil engraftment occurring in a median of just 8 days. Dr. Childs, who is also the Assistant U.S. Surgeon General, reflected on the findings:

"The results of this ongoing study are extremely encouraging and indicate a significant advancement in the treatment options for patients with a high unmet medical need."

One inspiring story comes from Erika Evans, who was diagnosed with acute myeloid leukemia (AML) in April 2012. Facing overwhelming odds, Erika underwent a double umbilical cord blood transplant at MD Anderson Cancer Center to ensure she received enough stem cells for treatment. By April 2017, she celebrated her five-year milestone of being cancer-free. Erika now shares her journey to uplift others:

"I want people to know it's possible not just to survive, but to thrive and to live a healthy, wonderful life again."

These personal accounts showcase how expanded cord blood therapies are reshaping outcomes for patients, especially those from diverse ethnic backgrounds who often face challenges finding bone marrow matches. These individual successes emphasize the potential of expanded cord blood technology as a game-changing treatment for blood cancers. They also highlight the importance of proactive cord blood banking, which ensures access to these life-saving therapies through resources like Americord Registry.

Cord Blood Banking: Preparing for the Future with Americord

Why Cord Blood Banking Matters

The potential of expanded cord blood therapies depends entirely on having stem cells available when needed. Since cord blood can only be collected at birth, private banking ensures immediate access to a compatible source of stem cells.

A high-quality cord blood unit is the starting point for life-saving treatments such as Omidubicel and NK cell therapy. These advanced therapies require a reliable and potent stem cell source. By banking at birth, families secure this critical resource for both current FDA-approved treatments and emerging therapies still under development.

Right now, cord blood stem cells are approved by the FDA to treat over 80 medical conditions, and more than 45,000 cord blood transplants have been performed worldwide. The odds of needing a stem cell transplant by age 70 are about 1 in 217. For families with a history of genetic conditions or those of mixed ethnicity - who often face challenges finding matches in public registries - private banking becomes even more essential.

Americord supports this need with advanced processing techniques and long-term storage options, ensuring families are prepared for both present and future medical advancements.

How Americord Supports Families

Americord builds on the advancements in expanded therapies by ensuring that stored stem cells remain viable for years to come. Their CryoMaxx™ Processing technology is designed to maximize stem cell recovery while preserving their potency. This means that families can trust their stored cells to remain effective even if needed decades later. Additionally, Americord uses 5-compartment storage bags instead of the standard 2-compartment ones, enabling families to use portions of their stored cells across multiple treatments without needing to thaw the entire sample.

Beyond cord blood, Americord offers comprehensive biobanking services. Families can also bank cord blood, cord tissue, and placenta tissue along with exosomes - each rich in different types of cells being studied in clinical trials for conditions like autism and Alzheimer’s. This multi-tissue approach gives families more options for future treatments as regenerative medicine continues to develop.

Americord also demonstrates its commitment through the Americord Cares Program, which provides free cord blood banking and lifetime storage for families with a child diagnosed with a condition treatable by an FDA-approved transplant. A notable example is Eli, whose parents used cord blood banked through this program to treat his Sickle Cell Disease. The treatment, performed at the Dana-Farber Cancer Institute, allowed Eli to return to school and normal activities by 2021.

Americord is FDA-registered and AABB-accredited, meeting the highest industry standards. They also offer a $110,000 Cord Blood Quality Guarantee, the most generous in the industry, which provides compensation if the cord blood fails to engraft during a transplant. Martin Smithmyer, Founder and CEO of Americord Registry, highlights their dedication:

"Our biggest hope is that families who bank their child's stem cells and perinatal tissues with Americord never need to use them. But if they do, we're always prepared to release them to the family's medical team for treatment quickly and efficiently."

Families can enroll as early as the second trimester. Americord provides a 4-in-1 collection kit that gathers cord blood, cord tissue, placental tissue, and exosomes in just 5–10 minutes during delivery. Their facility features 24/7-monitored cryo tanks equipped with temperature sensors and remote monitoring to ensure the long-term safety of stored stem cells. Costs range from $1,500 to $3,000 initially, with annual fees between $175 and $250, which can be covered using FSAs or HSAs.

Conclusion

Expanded cord blood therapies are transforming the way we approach treatment for blood cancers and other severe illnesses. Innovations like Omidubicel (Omisirge) have shown incredible results, such as a 94% survival rate in severe aplastic anemia and a dramatic reduction in neutrophil recovery time from 22 days to just 12. These advancements significantly lower infection risks and improve patient outcomes.

The FDA's approval of these therapies has set a new benchmark in care, particularly for high-risk patients and ethnic minorities who often face challenges in finding suitable bone marrow matches. What once seemed out of reach is now a viable treatment option, offering hope to those who need it most.

Cord blood banking and its benefits play a vital role in this progress. Since cord blood can only be collected at birth, families who bank these stem cells ensure a potential match for their child and siblings. This foresight connects innovation with preparedness, creating a foundation for both current treatments and the future of medicine. With over 500 clinical trials exploring therapies for conditions like autism and Alzheimer's, stored stem cells are not just a resource for today’s breakthroughs - they’re paving the way for tomorrow’s possibilities.

Robust cord blood banking is essential to support these advancements. Americord’s cutting-edge technologies, such as CryoMaxx™ Processing and 5-compartment storage vials, provide families with access to high-quality stem cells when they need them most. Backed by a $110,000 Cord Blood Quality Guarantee and rapid release protocols, Americord offers families the security and support they need to face future health challenges with confidence.

Banking cord blood isn’t just about preparation - it’s about creating options for your family. As Dr. Richard Childs, Assistant U.S. Surgeon General, stated:

"The results of this ongoing study are extremely encouraging and indicate a significant advancement in the treatment options for patients with a high unmet medical need."

For families considering cord blood banking, the landscape of medical treatments is growing rapidly. By banking today, you’re securing access to the therapies of tomorrow.

FAQs

Who is eligible for an expanded cord blood transplant?

Individuals who might benefit from expanded cord blood transplants are typically those dealing with severe blood disorders, such as severe aplastic anemia or specific types of blood cancers. This approach is often explored when treatment options are limited, particularly for patients undergoing myeloablative conditioning before transplantation. These therapies provide a potential lifeline for patients confronting complex and difficult-to-treat conditions.

What risks or side effects come with expanded cord blood therapy?

Expanded cord blood therapy, like other stem cell treatments, comes with potential risks. Short-term side effects often include fever, nausea, fatigue, headache, and chills. These are typically manageable with proper medical attention. However, more serious concerns, such as graft-versus-host disease (GVHD), infections, or even organ failure, can arise.

To minimize complications, the FDA has approved advancements aimed at improving safety. Still, close monitoring by skilled healthcare professionals remains essential to address any issues promptly and ensure patient safety throughout the treatment process.

Does banking cord blood with Americord improve my family’s chances of using these treatments?

Banking cord blood with Americord can increase your family’s opportunities to benefit from cutting-edge medical treatments. Stem cells stored from cord blood have already been used successfully to address conditions such as sickle cell disease and autism. As advancements in expanded cord blood therapies continue, these treatments are becoming more effective and available, opening the door to even broader medical possibilities in the years ahead.